Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Carboplatin + Paclitaxel & Ovarian cancer

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Regulatory status

In the context of Carboplatin + Paclitaxel & Ovarian cancer, Carboplatin + paclitaxel is an established standard chemotherapy backbone for epithelial ovarian cancer, but it is not a “co‑branded” fixed combination; each drug has its own label and the doublet is defined in guidelines and pivotal trials rather than as a single combo product (3, 4)

Clinical data

In a randomized clinical phase III trial known as NCT01654146 (ICON8),

it was discovered that among a group of predominantly European women with epithelial ovarian cancer, the use of first-line weekly dose-dense chemotherapy did not lead to improvements in overall or prog…

References (Sources)

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase III trial
Pignata et al. 2021 The Lancet Oncology 22: 267-276
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Monk et al. 2021 The Lancet Oncology 22: 1275-1289
Objective responses to ﬁrst-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase III trial
Morgan et al. 2021a The Lancet Oncology 22: 277-288
Primary ovarian cancer chemotherapy: current standards of care
McGuire 3rd & Markman 2003 Br J Cancer 89 Suppl_3): S3-8
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Kristeleit et al. 2022 The Lancet Oncology 23: 465-478
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
Clamp et al. 2019 Lancet 394(10214): 2084-2095
Weekly platinum-based chemotherapy vs 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase III, randomised, controlled trial
Blagden et al. 2020

AI Chat

7/1/2026

Chat with our artificial intelligence: